- Home
- XFOR vs SERA Comparison
XFOR vs SERA Comparison
Compare XFOR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- SERA
- Stock Information
- Founded
- XFOR 2014
- SERA 2008
- Country
- XFOR United States
- SERA United States
- Employees
- XFOR N/A
- SERA N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- SERA Precision Instruments
- Sector
- XFOR Health Care
- SERA Health Care
- Exchange
- XFOR Nasdaq
- SERA Nasdaq
- Market Cap
- XFOR 84.3M
- SERA 90.6M
- IPO Year
- XFOR N/A
- SERA 2021
- Fundamental
- Price
- XFOR $3.64
- SERA $3.38
- Analyst Decision
- XFOR Strong Buy
- SERA
- Analyst Count
- XFOR 3
- SERA 0
- Target Price
- XFOR $34.17
- SERA N/A
- AVG Volume (30 Days)
- XFOR 10.6M
- SERA 136.0K
- Earning Date
- XFOR 08-08-2025
- SERA 08-06-2025
- Dividend Yield
- XFOR N/A
- SERA N/A
- EPS Growth
- XFOR N/A
- SERA N/A
- EPS
- XFOR N/A
- SERA N/A
- Revenue
- XFOR $32,774,000.00
- SERA $108,000.00
- Revenue This Year
- XFOR $1,313.84
- SERA $257.66
- Revenue Next Year
- XFOR N/A
- SERA $435.22
- P/E Ratio
- XFOR N/A
- SERA N/A
- Revenue Growth
- XFOR 5721.31
- SERA 0.94
- 52 Week Low
- XFOR $1.35
- SERA $1.37
- 52 Week High
- XFOR $26.83
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- XFOR 51.62
- SERA 68.28
- Support Level
- XFOR $3.57
- SERA $2.77
- Resistance Level
- XFOR $4.83
- SERA $3.57
- Average True Range (ATR)
- XFOR 0.55
- SERA 0.31
- MACD
- XFOR -0.05
- SERA 0.12
- Stochastic Oscillator
- XFOR 26.94
- SERA 90.31
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.